First Wave BioPharma has filed a patent for compounds and compositions that can be used to treat coronavirus infections, including COVID-19. The methods involve administering niclosamide compounds to the patient, either through respiratory administration or administration to the gastrointestinal tract. GlobalData’s report on First Wave BioPharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights First Wave BioPharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on First Wave BioPharma, CRISPR genome editing was a key innovation area identified from patents. First Wave BioPharma's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230201143A1) describes a device designed to administer a composition containing niclosamide to the respiratory system of a subject. Niclosamide is a compound that has shown potential in various therapeutic applications. The device mentioned in the patent can be an inhalation device such as a nebulizer, metered dose inhaler, dry powder inhaler, or nasal spray.

The composition administered by the device may contain niclosamide ethanolamine, along with other pharmaceutically acceptable excipients. These excipients can include thickeners, viscosity enhancing agents, bulking agents, mucoadhesive agents, penetration enhancers, buffers, preservatives, diluents, binders, lubricants, glidants, disintegrants, fillers, solubilizing agents, pH modifying agents, stabilizing agents, anti-oxidants, wetting or emulsifying agents, suspending agents, pigments, colorants, isotonic agents, chelating agents, emulsifiers, and diagnostic agents.

Additionally, the composition may also contain polyvinylpyrrolidone and beta cyclodextrin. Other possible ingredients include sodium salicylate, citric acid, chitosans, phospholipids, fatty acids, fatty acid esters, glycerol, or combinations thereof.

The patent also mentions the use of nanoparticles, spray dried materials, engineered porous particles, and liposomes in the composition. These can enhance the delivery and effectiveness of the compound.

The device can be used for prophylactic purposes, meaning it can be used to prevent certain conditions or diseases. The composition's particle size distribution is specified to be between 1.0 µm and 10.0 µm.

Overall, this patent describes a device that can effectively administer a composition containing niclosamide to the respiratory system of a subject. The composition includes various excipients and can be used in different types of inhalation devices or as a nasal spray. The use of additional ingredients and delivery systems can enhance the therapeutic potential of niclosamide.

To know more about GlobalData’s detailed insights on First Wave BioPharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies